Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx 'Reenergized' By EU Zalviso Approval; Royalty Sell-Off To Fund US Fight Back

This article was originally published in Scrip

Executive Summary

AcelRx Pharmaceuticals Inc., which suffered a major setback last year when the US FDA refused to approve its lead product Zalviso (sufentanil sublingual tablets) for the treatment of post-operative pain, has been 'reenergized' by news that the product has been approved in Europe, management told Scrip. This follows news from earlier this week that AcelRx has sold the majority of the expected royalty stream from the sales of Zalviso in the EU to PDL BioPharma. AcelRx's commercial partner in the EU is Grunenthal GmbH.

Advertisement

Related Content

Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel